scholarly journals P8‐101: EGFR‐TKI treatment for squamous cell lung carcinoma with EGFR mutations

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 327-328
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Egfr Mutations ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Tki Treatment ◽  
Egfr Tki

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

2018 ◽  
Vol 23 (3) ◽  
pp. 452-457 ◽  
Author(s):  
Yuri Taniguchi ◽  
Yoko Matsumoto ◽  
Ryutaro Furukawa ◽  
Sayaka Ohara ◽  
Kazuhiro Usui
Keyword(s):  
Clinical Features ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Egfr Mutations ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma

scholarly journals A Rare EGFR R748T Mutation in A Squamous Cell Lung Carcinoma Patient with PD-L1 High Expression and Response to Immuno-Chemo Combination Therapy

2020 ◽  
Author(s):  
Ruifang Sun ◽  
Qianqian Duan ◽  
Guangyan Lei ◽  
Zhigang Liu
Keyword(s):  
Lung Cancer ◽  
Combination Therapy ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
High Expression ◽  
Egfr Mutations ◽  
Squamous Cell Lung Carcinoma ◽  
Primary Resistance ◽  
Ongoing Research ◽  
Cell Lung Carcinoma

Abstract Background: In present, patients with stage IV or recurrent/metastatic non-small cell lung cancer (NSCLC) whose tumors harbor programmed death ligand 1 (PD-L1) expression and active Epidermal Growth Factor Receptor (EGFR) mutations should receive initial EGFR tyrosine kinase inhibitors (TKIs) based on clinical guidelines and practice. However, high PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment advanced EGFR-mutant lung cancer patients, the optimal use of ICI therapy in patients with actionable EGFR mutations remains an important field of ongoing research. Some studies also showed that patients with uncommon EGFR mutations have a good immunotherapy potential.Case prestation: Here, we report a 56-year old advanced squamous cell lung carcinoma (SCC) patient with a rare active mutation in EGFR gene (EGFR p.R748T) and PD-L1 expression who responded well to the immune-chemo combination therapy (pembrolizumab with nab-paclitaxel and nedaplatin). Conclusion: The EGFR R748T mutation is an uncommon active mutation and there is no report about immuno-chemo therapy on patient with EGFR R748T mutation and PD-L1 high expression. The result presented in this case provides a feasible therapy for some patients who harbor rare active EGFR mutations (except for G719X, L861Q, S768I, and Ex20 ins) with high PD-L1 expression.

scholarly journals P1.02-055 Genotyping Squamous Cell Lung Carcinoma Among Hispanics (Geno1.1-CLICaP)

2017 ◽  
Vol 12 (11) ◽  
pp. S1944-S1945
Author(s):  
A. Cardona ◽  
O. Arrieta ◽  
L. Rojas ◽  
Z. Zatarain-Barron ◽  
L. Corrales ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma

scholarly journals Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma

2020 ◽  
Vol 125 (3) ◽  
pp. 257-261
Author(s):  
Virginija Šileikienė ◽  
Viktorija Gurskytė ◽  
Ingrida Zeleckienė ◽  
Elena Bernotienė ◽  
Sigitas Čibiras
Keyword(s):  
Pulmonary Artery ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Tumour Progression ◽  
Squamous Cell Lung Carcinoma ◽  
Coil Embolisation ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document